References
- Van den Bemt BJF, den Broeder AA, Wolbink G, et al. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-) response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol. 2013;76(6):939–945.
- Medina F, Plasencia C, Goupille P, et al. Current practice for therapeutic drug monitoring of iopharmaceuticals in rheumatoid arthritis. Ther Drug Monit. 2017;39(4):364–369.
- Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499–505.
- Inciarte-Mundo J, Ramirez J, Hernández MV, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18(1):1–13.
- Inciarte-Mundo J, Ruiz-Esquide V, Hernández MV, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology. 2015;53:1–5.
- Hansson C, Eriksson C, Alenius G. S-Calprotectin (S100A8/S100A9): a potential marker of inflammation in patients with psoriatic arthritis. J Immunol Res. 2014;2014:1–5.
- García-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis: association with disease activity in a cross-sectional and a longitudinal cohort. Mol Diagn Ther. 2013;17(1):49–56.
- Hammer HB, Odegard S, Syversen SW, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):150–154.
- Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50(8):1445–1452.